Está usted abandonando el sitio web de Lilly
La liga en la que hizo clic lo llevará a un sitio administrado por un tercero, quien es el único responsable de su contenido. ELI LILLY Y COMPAÑÍA DE MÉXICO S.A. DE C.V. no controla, influye o respalda este sitio, y las opiniones, reclamos o comentarios expresados en este sitio no son responsabilidad de ELI LILLY Y COMPAÑÍA DE MÉXICO S.A. DE C.V. y tampoco la política de privacidad de los sitios web de terceros. Le recomendamos que lea la política de privacidad de cada sitio web que visite. Haga clic en "Continuar" para proceder o "Regresar" para mantenerse en LillyMedical.com/mx
Haga una pregunta para buscar información del producto y recursos médicos de Lilly. Para activar la búsqueda escriba 3 términos.
Por favor no use este campo para reportar eventos adverso o quejas de productos.
Para consultar la información para prescribir completa de Olumiant® (Baricitinib) de clic en el siguiente enlace:
Información para prescribir
La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.
Baricitinib: Use in Patients With a History of Malignancy
Baricitinib (BARI) was not systematically studied in patients with moderate to severe RA and malignant disease.
Clinical Trial Criteria
Patients with a history of malignancy were not uniformly excluded from the BARI phase 3 clinical development program.1
Patients who were able to participate in the BARI phase 3 clinical trials included patients with
cervical carcinoma in situ that had been resected with no evidence of recurrence or metastatic disease for at least 3 years, and
basal cell or squamous epithelial skin cancers that had been completely resected with no evidence of recurrence for at least 3 years.1
However, patients were excluded from the phase 3 trials if they had
a history of lymphoproliferative disease
signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly
active primary or recurrent malignant disease, or
been in remission from clinically significant malignancy for <5 years.1
Baricitinib Phase 3 Program
Each of the 4 phase 3 studies in the clinical program evaluated a distinct treatment population of patients with moderate-to-severe RA.
RA-BEGIN compared BARI 4 mg monotherapy, BARI 4 mg plus MTX, and MTX monotherapy in patients who had limited or no prior treatment with MTX and were naïve to other DMARDs.2
RA-BEAM compared BARI 4 mg vs placebo or adalimumab, with background MTX, in patients with inadequate response to MTX.3
RA-BUILD compared BARI 2 mg and 4 mg vs placebo, with background csDMARD therapy, in patients with inadequate response to csDMARDs.4
RA-BEACON compared BARI 2 mg and 4 mg vs placebo, with background csDMARD therapy, in patients with an inadequate response to at least one TNF inhibitor, who may also have had an inadequate response to one or more non-TNF inhibitor biologic DMARDs.5
Patients With Medical History of Malignancy in the Baricitinib Phase 3 Program
Medical history, including malignancy, was recorded upon enrollment into each of the BARI phase 3 clinical studies.1
A history of malignancy was defined as malignancy that was previously diagnosed and resolved prior to study entry.1
Efficacy and Safety Analysis of Patients With a History of Malignancy
The individual phase 3 clinical trials were not designed to detect differences in the efficacy and safety of BARI for the treatment of moderate to severe RA in patients with or without a medical history or pre-existing condition of malignancy. Due to the small numbers of patients with a medical history or preexisting condition of malignancy in the BARI phase 3 clinical program for RA, an analysis of the efficacy and safety of BARI in these patients is not feasible.
Comorbid Conditions of Special Interest in the Baricitinib Phase 3 Studies1
Selected preexisting conditions (mITT)
Malignancies, n (%)
Selected historical diagnoses (mITT)
Malignancies, n (%)
Abbreviations: mITT = modified intent-to-treat. Percentages are based on the number of patients in the analysis.
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506-517. http://dx.doi.org/10.1002/art.39953